Why the study?
Primary cardiac synovial sarcoma is rare and aggressive with undefined treatment guidelines, especially in pregnant women.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Radical resection and mechanical tricuspid valve replacement can be successfully performed in a pregnant woman with primary cardiac synovial sarcoma, ensuring both maternal and fetal survival.
Primary cardiac synovial sarcoma (PCSS) is a rare and highly aggressive tumor with a significant mortality rate. Treatment guidelines have not been defined given the relative rarity of the condition, especially for pregnant women. Described herein is a 36-year-old pregnant woman at 29 weeks with gestation who was hospitalized due to chest tightness and nausea, and echocardiography found a mass involved in the right heart and the tricuspid valve. She had to undergo cardiac surgery because the mass almost blocked the opening of the tricuspid valve. She underwent a radical resection of the masses and tricuspid valve, followed by replacement of the tricuspid valve with a mechanical valve. She successfully delivered a healthy baby boy. The diagnosis of synovial sarcoma is confirmed by positive results indicating rearrangement of the SYT gene. The patient survived throughout the 30-month follow-up period. There are no reported cases of pregnant women diagnosed with cardiac synovial sarcoma and have undergone cardiac surgery and cesarean section. Our treatment plan not only maximizes patient survival but also ensures fetal survival. This situation is rare and needs documentation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted a case report in Primary cardiac synovial sarcoma (n=1). Surgical resection and tricuspid valve replacement on cardiopulmonary bypass, followed by cesarean section and adjuvant chemotherapy was evaluated on Maternal and fetal survival.
Synapse has enriched 10 related papers. Consider them for comparative context: